• Home
  • Congress & Events
  • ISPOR 2023
  • Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis

ISPOR 2023

May 07 - May 10, 2023 | Boston, USA

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis

Authors Dominic Voehler; Patricia G. Synnott; Thomas Majda; Daniel A. Ollendorf; Pei-Jung Lin; Stacey Kowal

Published date08 May, 2023

Distributional cost-effectiveness analysis (DCEA) can quantify the potential impact of Alzheimer’s Disease (AD) and its treatment on concerns of health equity. We conducted a literature search to identify studies that investigated the impact of race/ethnicity and social determinants of health on AD outcomes relevant to economic modeling. We identified gaps in the evidence that highlight the need for systematic data collection across equity-relevant subgroups, particularly groups defined by level of social vulnerability. Despite uncertainties, there is sufficient evidence available to evaluate the distributional impact of emerging AD therapies.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

Not a healthcare professional? Browse:

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.